OSI-027

DB12387InvestigationalSmall molecule

OSI-027 has been used in trials studying the treatment of Any Solid Tumor or Lymphoma.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₁H₂₂N₆O₃ · 406.446 g/mol (avg)
Also known as: CYCLOHEXANECARBOXYLIC ACID, 4-(4-AMINO-5-(7-METHOXY-1H-INDOL-2-YL)IMIDAZO(5,1-F)(1,2,4)TRIAZIN-7-YL)-, TRANS-
Code names: AEVI-006 · ASP-7486 · CERC-006 · OSI-027

Resolves to

Compound

Structure

InChIKeyJROFGZPOBKIAEW-HAQNSBGRSA-NSMILESCOC1=C2NC(=CC2=CC=C1)C1=C2N(N=CN=C2N)C(=N1)[C@H]1CC[C@@H](CC1)C(O)=O

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

28Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with OSI-027, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.